EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ObsEva SA (OBSEF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of ObsEva SA $0.00, price $0.00, upside +70.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Switzerland · ISIN CH1260041939

OS ObsEva SA logo Thin data Oct 3, 2026

ObsEva SA

OBSEF · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

Fair value $0.0002 · Strongly undervalued (+70.0%)
Highly profitable · 40.3% net margin (TTM)
Low debt
Ranks above peers (5/6)
Quality 40/100
Moderate moat 58/100
Weak Growth (revenue YoY −11.5 %/yr in USD)
Negative free cash flow
Thin data
Watch ObsEva SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.1000 $0.0001 Fair Value $0.0002 Jun 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

40‑month range $0.0001 – $0.1000 · fair‑value band $0.0001 – $0.0002 · the $0.0001 price screens below the $0.0002 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow ObsEva in your weekly email

Every Wednesday you see whether ObsEva is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Stock analysis

ObsEva SA (OBSEF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0002, implying the stock looks roughly 41.2% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the evidence level at low.

Scenario range: $0.0001 (bear) to $0.0002 (bull), the price of $0.0001 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

ObsEva SA reported revenue of $19.6M in FY2022 versus $0 in FY2019. Reported net income was −$29.9M in FY2022.

Key figures

Market cap $11.7K · EPS (TTM) $−0.3200 · Net margin 40.3% · Return on equity 15.8% · Return on assets (EBIT) −102% · Operating margin −95,057% · Revenue (TTM) $19.6M · Free cash flow −$23.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 70%, OBSEF screens cheaper than that median.

Fair Value models

Bear $0.0001 Fair Value $0.0002 Bull $0.0002
Price $0.0001 · Upside +70.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0001 $0.0002 $0.0002 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0002 $0.0002 54

Open the full fair value analysis →

Notify me when OBSEF reaches fair value

Put OBSEF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 40 · Market factors (momentum, volatility) 32

Profitability 23
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 30
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
not computed

Watch OBSEF, get fair value alerts →

Compare ObsEva SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 608 stocks

Beats the industry median on 4/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside +70.0% · Top 25%
Profitability
Return on equity (TTM) 15.8% · Top 25%
Return on assets 10.1% · Top 25%
Net margin (TTM) 40.3% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)63 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ObsEva SA · Fair Value
$0.0002 +41%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ObsEva SA Fair Value". https://www.fairvalue-calculator.com/stock/OBSEF

Frequently asked questions

Is ObsEva SA (OBSEF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0002 versus a price of $0.0001, about +70% upside (undervalued).
What is the fair value of OBSEF?
Our model-based fair value for ObsEva SA is $0.0002 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of OBSEF?
ObsEva SA has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ObsEva SA (OBSEF)?
Our model-based price target is the fair value of $0.0002 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $0.0001, optimistic scenario $0.0002. It is a calculation from audited fundamentals, not an analyst target.
What is the ObsEva SA stock forecast for 2026?
Our models put fair value at $0.0002, about +70% upside versus a price of $0.0001 (undervalued). Cautious scenario $0.0001, optimistic scenario $0.0002. The calculation is refreshed regularly with new filings.
What is the revenue of ObsEva SA (OBSEF)?
ObsEva SA reported trailing-twelve-month revenue of about $19.6M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of ObsEva SA (OBSEF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ObsEva SA it is $0.0002 per share (as of Oct 3, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ObsEva SA stock overvalued or undervalued in 2026?
As of Oct 3, 2026, OBSEF trades below its calculated fair value: price $0.0001, fair value $0.0002, a gap of about +70% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBSEF?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0002). For ObsEva SA the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is ObsEva SA worth?
The market values ObsEva SA at about $11.7K (market capitalisation, as of Oct 3, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0002 per share.
What do the bullish and bearish scenarios say about OBSEF?
Our models span a range for ObsEva SA: cautious scenario $0.0001, base $0.0002, optimistic $0.0002 per share (as of Oct 3, 2026, price $0.0001). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ObsEva SA (OBSEF)?
Balance-sheet figures for ObsEva SA (as of Oct 3, 2026): return on equity 15.8%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is OBSEF from its 52-week high?
ObsEva SA trades at $0.0001, about 90% below its 52-week high of $0.0010 and at the low of $0.0001 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0002 is for.
Which stocks are comparable to ObsEva SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ObsEva SA stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0001, calculated fair value $0.0002 (+70%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OBSEF calculated?
We run ObsEva SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0002, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. ObsEva SA currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ObsEva SA (OBSEF)?
The closing price on Oct 2, 2026 was $0.0001. Our model-based fair value is $0.0002, about +70% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ObsEva SA right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.0001). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ObsEva SA

How large is the market capitalisation of ObsEva SA (OBSEF)?
The market capitalisation of ObsEva SA is $11.7K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ObsEva SA (OBSEF)?
Earnings per share at ObsEva SA are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ObsEva SA (OBSEF)?
The net margin of ObsEva SA is 40.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ObsEva SA (OBSEF)?
The return on equity (ROE) of ObsEva SA is 15.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ObsEva SA (OBSEF)?
On an EBIT basis the return on assets of ObsEva SA is −102% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ObsEva SA (OBSEF)?
The operating margin of ObsEva SA is −95,057% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does ObsEva SA (OBSEF) generate?
The free cash flow of ObsEva SA is −$23.1M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ObsEva SA in the live analysis

One click puts ObsEva SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.